focus -WSS

focus

author：fashion 2025-10-01 00:47:35 - browse：5

A man enters the Regeneron Clinic at a monoclonal antibody treatment site in Pembroke Pines, Florida – politics and policy coverage from STAT — Regeneron agreed to price limits for a new Covid-19 drug that will be developed in partnership with the Department of Health and Human Services. CHANDAN KHANNA/AFP via Getty Images

WASHINGTON — A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.

The contract between Regeneron and the government requires that the list price for a future monoclonal antibody drug to prevent Covid-19 is the same or lower in the United States as in other high-income countries. The release doesn’t explain which countries the government will be comparing prices with, or how pricing data will be determined.

The deal was part of the White House’s Project NextGen initiative, which includes $5 billion in new vaccines and therapies. HHS announced that it is spending $326 million to help Regeneron develop a new monoclonal antibody to prevent Covid-19. Regeneron in January announced plans to start testing a potentially variant-proof antibody, which is set to go into clinical trials later this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

explore

WSS

The strange history of BMI, the body mass index

A virus, fished out of a lake, may have saved a man’s life

Medical experts exlpore how to eliminate bias in clinical algorithms

Bristol 'take

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

Was Amgen transparent enough on FDA's concern on cancer drug?

hotspot

focus

entertainment

State Dept. review finds Biden bears some blame for Afghanistan failures

The simple reason for the increase in autism diagnosis

Bright Health sells Medicare Advantage business to Molina

Supreme Court rules employers must be more accommodating of religious observance

In Memoriam: Notable people who died in 2023

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

The high cost of giving birth even with insurance

Supreme Court strikes down Biden student loan forgiveness program

How one medical school became remarkably diverse

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

leisure time

Supreme Court rules employers must be more accommodating of religious observance

Chemotherapy drug shortage eases slightly but still widespread

FDA panel signals lack of confidence in Amgen cancer drug data

Supreme Court strikes down Biden student loan forgiveness program

The sun may be out, but guns are not. A lawsuit challenges a new gun ban on Hawaii beaches

3 questions for the future of Biden's cancer moonshot

entertainment

explore

entertainment

leisure time